Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
- 21 September 2021
- journal article
- research article
- Published by Elsevier BV in International Journal of Pharmaceutics
- Vol. 608, 121122
- https://doi.org/10.1016/j.ijpharm.2021.121122
Abstract
No abstract availableFunding Information
- Queensland University of Technology
- Deanship of Scientific Research, King Faisal University (G.R.P. 138)
- King Khalid University
This publication has 40 references indexed in Scilit:
- Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- An Investigation into the Dispersion Mechanisms of Ternary Dry Powder Inhaler Formulations by the Quantification of Interparticulate ForcesPharmaceutical Research, 2007
- Quantification of phases with partial or no known crystal structuresPowder Diffraction, 2006
- Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixturesJournal of Pharmaceutical Sciences, 2004
- Lactose Surface Modification by Decantation: Are Drug-Fine Lactose Ratios the Key to Better Dispersion of Salmeterol Xinafoate from Lactose-Interactive Mixtures?Pharmaceutical Research, 2004
- In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro depositionInternational Journal of Pharmaceutics, 1997
- Review of dry powder inhalersAdvanced Drug Delivery Reviews, 1997
- Interactions of Warfarin with Drugs and FoodAnnals of Internal Medicine, 1994
- Ordered mixing in direct compression of tabletsPowder Technology, 1976